T1	Participants 703 883	previously untreated adult APL patients registered to protocol INT 0129 by the Eastern Cooperative Oncology Group, the Southwest Oncology Group, and the Cancer and Leukemia Group B
T2	Participants 885 949	Of 279 clinically eligible cases, 230 were molecularly evaluable
T3	Participants 199 233	acute promyelocytic leukemia (APL)
